Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIANCE: Adjuvant Atezolizumab After Cisplatin + Vinorelbine in Elderly Resected Stage II/III NSCLC
jRCTs071230065Phase 2Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Completion rate of protocol treatment. Started Oct 2023; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071230065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230065.